{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:42:22Z","timestamp":1791837742834,"version":"4.3.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National major science and technology project","award":["019YFC1710100"],"award-info":[{"award-number":["019YFC1710100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In recent decades, the prevalence of metabolic diseases, particularly diabetes, hyperlipidemia, obesity, and non-alcoholic fatty liver disease (NAFLD), has increased dramatically, causing great public health and economic burdens worldwide. Traditional Chinese medicine (TCM) serves as an effective therapeutic choice. Xiao-Ke-Yin (XKY) is a medicine and food homology TCM formula consisting of nine \u201cmedicine and food homology\u201d herbs and is used to ameliorate metabolic diseases, such as insulin resistance, diabetes, hyperlipidemia and NAFLD. However, despite its therapeutic potential in metabolic disorders, the underlying mechanisms of this TCM remain unclear. This study aimed to evaluate the therapeutic effectiveness of XKY on glucolipid metabolism dysfunction and explore the potential mechanisms in\n                      <jats:italic>db\/db<\/jats:italic>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To verify the effects of XKY,\n                      <jats:italic>db\/db<\/jats:italic>\n                      mice were treated with different concentrations of XKY (5.2, 2.6 and 1.3\u00a0g\/kg\/d) and metformin (0.2\u00a0g\/kg\/d, a hypoglycemic positive control) for 6 weeks, respectively. During this study, we detected the body weight (BW) and fasting blood glucose (FBG), oral glucose tolerance test (OGTT), insulin tolerance test (ITT), daily food intake and water intake. At the end of the animal experiment, blood samples, feces, liver and intestinal tissue of mice in all groups were collected. The potential mechanisms were investigated by using hepatic RNA sequencing, 16\u00a0S rRNA sequencing of the gut microbiota and metabolomics analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      XKY efficiently mitigated hyperglycemia, IR, hyperlipidemia, inflammation and hepatic pathological injury in a dose dependent manner. Mechanistically, hepatic transcriptomic analysis showed that XKY treatment significantly reversed the upregulated cholesterol biosynthesis which was further confirmed by RT-qPCR. Additionally, XKY administration maintained intestinal epithelial homeostasis, modulated gut microbiota dysbiosis, and regulated its metabolites. In particular, XKY decreased secondary bile acid producing bacteria (\n                      <jats:italic>Clostridia<\/jats:italic>\n                      and\n                      <jats:italic>Lachnospircaeae<\/jats:italic>\n                      ) and lowered fecal secondary bile acid (lithocholic acid (LCA) and deoxycholic acid (DCA)) levels to promote hepatic bile acid synthesis by inhibiting the LCA\/DCA-FXR-FGF15 signalling pathway. Furthermore, XKY regulated amino acid metabolism including arginine biosynthesis, alanine, aspartate and glutamate metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and tryptophan metabolism likely by increasing\n                      <jats:italic>Bacilli<\/jats:italic>\n                      ,\n                      <jats:italic>Lactobacillaceae<\/jats:italic>\n                      and\n                      <jats:italic>Lactobacillus<\/jats:italic>\n                      , and decreasing\n                      <jats:italic>Clostridia<\/jats:italic>\n                      ,\n                      <jats:italic>Lachnospircaeae<\/jats:italic>\n                      ,\n                      <jats:italic>Tannerellaceae<\/jats:italic>\n                      and\n                      <jats:italic>Parabacteroides<\/jats:italic>\n                      abundances.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, our findings demonstrate that XKY is a promising \u201cmedicine food homology\u201d formula for ameliorating glucolipid metabolism and reveal that the therapeutic effects of XKY may due to its downregulation of hepatic cholesterol biosynthesis and modulation of the dysbiosis of the gut microbiota and metabolites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-023-00752-6","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T04:03:15Z","timestamp":1684382595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Therapeutic mechanisms of the medicine and food homology formula Xiao-Ke-Yin on glucolipid metabolic dysfunction revealed by transcriptomics, metabolomics and microbiomics in mice"],"prefix":"10.1186","volume":"18","author":[{"given":"Mei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-3494","authenticated-orcid":false,"given":"Anlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"752_CR1","doi-asserted-by":"publisher","first-page":"110984","DOI":"10.1016\/j.biopha.2020.110984","volume":"133","author":"X Xu","year":"2021","unstructured":"Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, Du H, Xu T, Jiang G, Fan G. Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence. Biomed Pharmacother. 2021;133:110984.","journal-title":"Biomed Pharmacother"},{"key":"752_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"752_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110:921\u201337.","journal-title":"Clin Res Cardiol"},{"key":"752_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145\u201371.","journal-title":"Annu Rev Pathol"},{"key":"752_CR5","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"752_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","volume":"55","author":"H Hu","year":"2020","unstructured":"Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol. 2020;55:142\u201358.","journal-title":"J Gastroenterol"},{"key":"752_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1566524015666150114110551","volume":"15","author":"R Ordonez","year":"2015","unstructured":"Ordonez R, Carbajo-Pescador S, Mauriz JL, Gonzalez-Gallego J. Understanding nutritional interventions and physical exercise in non-alcoholic fatty liver disease. Curr Mol Med. 2015;15:3\u201326.","journal-title":"Curr Mol Med"},{"key":"752_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1927633","volume":"13","author":"Y Rao","year":"2021","unstructured":"Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13:1\u201319.","journal-title":"Gut Microbes"},{"key":"752_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.tips.2021.09.003","volume":"42","author":"X Zhang","year":"2021","unstructured":"Zhang X, Cai X, Zheng X. Gut microbiome-oriented therapy for metabolic diseases: challenges and opportunities towards clinical translation. Trends Pharmacol Sci. 2021;42:984\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"752_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3350\/cmh.2020.0125","volume":"27","author":"NY Lee","year":"2021","unstructured":"Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, et al. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2021;27:110\u201324.","journal-title":"Clin Mol Hepatol"},{"key":"752_CR11","doi-asserted-by":"publisher","first-page":"2093171","DOI":"10.1155\/2016\/2093171","volume":"2016","author":"X Yan","year":"2016","unstructured":"Yan X, Feng B, Li P, Tang Z, Wang L. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study. J Diabetes Res. 2016;2016:2093171.","journal-title":"J Diabetes Res"},{"key":"752_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/gutjnl-2020-323071","volume":"70","author":"A Agus","year":"2021","unstructured":"Agus A, Clement K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70:1174\u201382.","journal-title":"Gut"},{"key":"752_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1586\/17474124.2015.1057122","volume":"9","author":"K Brandl","year":"2015","unstructured":"Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015;9:1069\u201376.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"752_CR14","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020;21:5214.","journal-title":"Int J Mol Sci"},{"key":"752_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359\u201370.","journal-title":"Gut"},{"key":"752_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","volume":"27","author":"A Mardinoglu","year":"2018","unstructured":"Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, Rasanen SM, Lee S, Mancina RM, Bergentall M, Pietilainen KH, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab. 2018;27:559-571e555.","journal-title":"Cell Metab"},{"key":"752_CR17","doi-asserted-by":"publisher","first-page":"dmm039206","DOI":"10.1242\/dmm.039206","volume":"12","author":"S Carbajo-Pescador","year":"2019","unstructured":"Carbajo-Pescador S, Porras D, Garcia-Mediavilla MV, Martinez-Florez S, Juarez-Fernandez M, Cuevas MJ, Mauriz JL, Gonzalez-Gallego J, Nistal E, Sanchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech. 2019;12:dmm039206.","journal-title":"Dis Model Mech"},{"key":"752_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3920\/BM2012.0065","volume":"5","author":"L Geurts","year":"2014","unstructured":"Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014;5:3\u201317.","journal-title":"Benef Microbes"},{"key":"752_CR19","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.3390\/ijms21093066","volume":"21","author":"Y Ji","year":"2020","unstructured":"Ji Y, Yin Y, Sun L, Zhang W. The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement. Int J Mol Sci. 2020;21:3066.","journal-title":"Int J Mol Sci."},{"key":"752_CR20","doi-asserted-by":"publisher","first-page":"110857","DOI":"10.1016\/j.biopha.2020.110857","volume":"133","author":"HY Zhang","year":"2021","unstructured":"Zhang HY, Tian JX, Lian FM, Li M, Liu WK, Zhen Z, Liao JQ, Tong XL. Therapeutic mechanisms of traditional chinese medicine to improve metabolic diseases via the gut microbiota. Biomed Pharmacother. 2021;133:110857.","journal-title":"Biomed Pharmacother"},{"key":"752_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/foods9020142","volume":"9","author":"MY Ji","year":"2020","unstructured":"Ji MY, Bo A, Yang M, Xu JF, Jiang LL, Zhou BC, Li MH. The pharmacological effects and health benefits of Platycodon grandiflorus: a medicine food homology species. Foods. 2020;9:142.","journal-title":"Foods."},{"key":"752_CR22","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3389\/fmicb.2017.02146","volume":"8","author":"M Lyu","year":"2017","unstructured":"Lyu M, Wang YF, Fan GW, Wang XY, Xu SY, Zhu Y. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota. Front Microbiol. 2017;8:2146.","journal-title":"Front Microbiol"},{"key":"752_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1039\/C3FO60524H","volume":"5","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang H, Ji B, Cai S, Wang R, Zhou F, Yang J, Liu H. A diet formula of Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma alleviates insulin resistance and hepatic steatosis in CD-1 mice and HepG2 cells. Food Funct. 2014;5:1038\u201349.","journal-title":"Food Funct"},{"key":"752_CR24","doi-asserted-by":"publisher","first-page":"154452","DOI":"10.1016\/j.phymed.2022.154452","volume":"107","author":"C Cheng","year":"2022","unstructured":"Cheng C, Hu J, Li Y, Ji Y, Lian Z, Au R, Xu F, Li W, Shen H, Zhu L. Qing-Chang-Hua-Shi granule ameliorates DSS-induced colitis by activating NLRP6 signaling and regulating Th17\/Treg balance. Phytomedicine. 2022;107:154452.","journal-title":"Phytomedicine"},{"key":"752_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41419-018-1077-9","volume":"9","author":"M Li","year":"2018","unstructured":"Li M, Chai HF, Peng F, Meng YT, Zhang LZ, Zhang L, Zou H, Liang QL, Li MM, Mao KG, et al. Estrogen receptor beta upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death Dis. 2018;9:1120.","journal-title":"Cell Death Dis"},{"key":"752_CR26","doi-asserted-by":"publisher","first-page":"108336","DOI":"10.1016\/j.jnutbio.2019.108336","volume":"78","author":"H Zeng","year":"2020","unstructured":"Zeng H, Larson KJ, Cheng WH, Bukowski MR, Safratowich BD, Liu Z, Hakkak R. Advanced liver steatosis accompanies an increase in hepatic inflammation, colonic, secondary bile acids and Lactobacillaceae\/Lachnospiraceae bacteria in C57BL\/6 mice fed a high-fat diet. J Nutr Biochem. 2020;78:108336.","journal-title":"J Nutr Biochem"},{"key":"752_CR27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56:1034\u201343.","journal-title":"Hepatology"},{"key":"752_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103:e1\u201313.","journal-title":"Transplantation"},{"key":"752_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/molecules23051170","volume":"23","author":"X Cui","year":"2018","unstructured":"Cui X, Wang S, Cao H, Guo H, Li Y, Xu F, Zheng M, Xi X, Han C. A review: the bioactivities and pharmacological applications of Polygonatum sibiricum polysaccharides. Molecules. 2018;23:1170.","journal-title":"Molecules"},{"key":"752_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1535370216663866","volume":"242","author":"Y Wang","year":"2017","unstructured":"Wang Y, Qin S, Pen G, Chen D, Han C, Miao C, Lu B, Su C, Feng S, Li W, et al. Original research: potential ocular protection and dynamic observation of Polygonatum sibiricum polysaccharide against streptozocin-induced diabetic rats\u2019 model. Exp Biol Med (Maywood). 2017;242:92\u2013101.","journal-title":"Exp Biol Med (Maywood)"},{"key":"752_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.phymed.2017.01.007","volume":"26","author":"H Yan","year":"2017","unstructured":"Yan H, Lu J, Wang Y, Gu W, Yang X, Yu J. Intake of total saponins and polysaccharides from Polygonatum kingianum affects the gut microbiota in diabetic rats. Phytomedicine. 2017;26:45\u201354.","journal-title":"Phytomedicine"},{"key":"752_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jpp\/rgab041","volume":"73","author":"F Li","year":"2021","unstructured":"Li F, Song L, Chen J, Chen Y, Li Y, Huang M, Zhao W. Effect of genipin-1-beta-d-gentiobioside on diabetic nephropathy in mice by activating AMP-activated protein kinase\/silencing information regulator-related enzyme 1\/nuclear factor-kappab pathway. J Pharm Pharmacol. 2021;73:1201\u201311.","journal-title":"J Pharm Pharmacol"},{"key":"752_CR33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.jafc.7b06082","volume":"66","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Men L, Pi Z, Wei M, Song F, Zhao C, Liu Z. Fecal metabolomics of type 2 diabetic rats and treatment with Gardenia jasminoides Ellis based on Mass Spectrometry technique. J Agric Food Chem. 2018;66:1591\u20139.","journal-title":"J Agric Food Chem"},{"key":"752_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/febs.14349","volume":"285","author":"H Zhong","year":"2018","unstructured":"Zhong H, Chen K, Feng M, Shao W, Wu J, Chen K, Liang T, Liu C. Genipin alleviates high-fat diet-induced hyperlipidemia and hepatic lipid accumulation in mice via miR-142a-5p\/SREBP-1c axis. FEBS J. 2018;285:501\u201317.","journal-title":"FEBS J"},{"key":"752_CR35","doi-asserted-by":"publisher","first-page":"104945","DOI":"10.1016\/j.phrs.2020.104945","volume":"159","author":"X Fan","year":"2020","unstructured":"Fan X, Lin L, Cui B, Zhao T, Mao L, Song Y, Wang X, Feng H, Qingxiang Y, Zhang J, et al. Therapeutic potential of genipin in various acute liver injury, fulminant hepatitis, NAFLD and other non-cancer liver diseases: more friend than foe. Pharmacol Res. 2020;159:104945.","journal-title":"Pharmacol Res"},{"key":"752_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.carbpol.2012.04.049","volume":"89","author":"M Jin","year":"2012","unstructured":"Jin M, Zhao K, Huang Q, Xu C, Shang P. Isolation, structure and bioactivities of the polysaccharides from Angelica sinensis (Oliv.) Diels: a review. Carbohydr Polym. 2012;89:713\u201322.","journal-title":"Carbohydr Polym"},{"key":"752_CR37","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1039\/C6FO01196A","volume":"7","author":"K Wang","year":"2016","unstructured":"Wang K, Tang Z, Zheng Z, Cao P, Shui W, Li Q, Zhang Y. Protective effects of Angelica sinensis polysaccharide against hyperglycemia and liver injury in multiple low-dose streptozotocin-induced type 2 diabetic BALB\/c mice. Food Funct. 2016;7:4889\u201397.","journal-title":"Food Funct"},{"key":"752_CR38","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1002\/jsfa.8323","volume":"97","author":"A Aierken","year":"2017","unstructured":"Aierken A, Buchholz T, Chen C, Zhang X, Melzig MF. Hypoglycemic effect of hawthorn in type II diabetes mellitus rat model. J Sci Food Agric. 2017;97:4557\u201361.","journal-title":"J Sci Food Agric"},{"key":"752_CR39","doi-asserted-by":"publisher","first-page":"115240","DOI":"10.1016\/j.jep.2022.115240","volume":"293","author":"Y He","year":"2022","unstructured":"He Y, Huang L, Jiang P, Xu G, Sun T. Immunological regulation of the active fraction from Polygonatum sibiricum F. Delaroche based on improvement of intestinal microflora and activation of RAW264.7 cells. J Ethnopharmacol. 2022;293:115240.","journal-title":"J Ethnopharmacol"},{"key":"752_CR40","doi-asserted-by":"publisher","first-page":"111325","DOI":"10.1016\/j.biopha.2021.111325","volume":"137","author":"Y Liu","year":"2021","unstructured":"Liu Y, Qiu Y, Chen Q, Han X, Cai M, Hao L. Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K\/Akt signaling pathway in diabetic rats and HepG(2) cells. Biomed Pharmacother. 2021;137:111325.","journal-title":"Biomed Pharmacother"},{"key":"752_CR41","doi-asserted-by":"publisher","first-page":"e81724","DOI":"10.1371\/journal.pone.0081724","volume":"8","author":"M Gu","year":"2013","unstructured":"Gu M, Zhang Y, Fan S, Ding X, Ji G, Huang C. Extracts of Rhizoma polygonati odorati prevent high-fat diet-induced metabolic disorders in C57BL\/6 mice. PLoS ONE. 2013;8:e81724.","journal-title":"PLoS ONE"},{"key":"752_CR42","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.3390\/molecules25153356","volume":"25","author":"H Wu","year":"2020","unstructured":"Wu H, Huang Q, Chao S, Yu J, Xu S, Wang F, Shang X, Zhu Y. Determination of ferulic acid in Angelica sinensis by temperature-controlled hydrophobic ionic liquids-based ultrasound\/heating-assisted extraction coupled with high performance liquid chromatography. Molecules. 2020;25:3356.","journal-title":"Molecules."},{"key":"752_CR43","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1039\/C9FO02398D","volume":"11","author":"MY Qi","year":"2020","unstructured":"Qi MY, Wang XT, Xu HL, Yang ZL, Cheng Y, Zhou B. Protective effect of ferulic acid on STZ-induced diabetic nephropathy in rats. Food Funct. 2020;11:3706\u201318.","journal-title":"Food Funct"},{"key":"752_CR44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrendo.2017.80","volume":"13","author":"MC Petersen","year":"2017","unstructured":"Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572\u201387.","journal-title":"Nat Rev Endocrinol"},{"key":"752_CR45","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u201327.","journal-title":"Cell Mol Life Sci"},{"key":"752_CR46","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196.","journal-title":"J Diabetes Res"},{"key":"752_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"752_CR48","doi-asserted-by":"publisher","first-page":"680081","DOI":"10.3389\/fphar.2021.680081","volume":"12","author":"B Yang","year":"2021","unstructured":"Yang B, Sun J, Liang S, Wu P, Lv R, He Y, Li D, Sun W, Song X. Prediction of Srebp-1 as a key target of Qing Gan San against MAFLD in rats via RNA-sequencing profile analysis. Front Pharmacol. 2021;12:680081.","journal-title":"Front Pharmacol"},{"key":"752_CR49","doi-asserted-by":"crossref","unstructured":"Zhang Z, Ho WK, Huang Y, et al. Hawthorn fruit is hypolipidemic in rabbits fed a high cholesterol diet [J]. J Nutr. 2002;132(1):5\u201310.","DOI":"10.1093\/jn\/132.1.5"},{"key":"752_CR50","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jff.2013.04.020","volume":"5","author":"C-Y Kwok","year":"2013","unstructured":"Kwok C-Y, Li C, Cheng H-L, Ng Y-F, Chan T-Y, Kwan Y-W, Leung GP-H, Lee SM-Y, Mok DK-W, Yu PH-F, Chan S-W. Cholesterol lowering and vascular protective effects of ethanolic extract of dried fruit of Crataegus pinnatifida, hawthorn (Shan Zha), in diet-induced hypercholesterolaemic rat model. J Funct Foods. 2013;5:1326\u201335.","journal-title":"J Funct Foods"},{"key":"752_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14218\/JCTH.2018.00008","volume":"7","author":"L Campo","year":"2019","unstructured":"Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty liver disease and gut microbiota: a comprehensive update. J Clin Transl Hepatol. 2019;7:56\u201360.","journal-title":"J Clin Transl Hepatol"},{"key":"752_CR52","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3389\/fmicb.2019.01423","volume":"10","author":"HX Cui","year":"2019","unstructured":"Cui HX, Zhang LS, Luo Y, Yuan K, Huang ZY, Guo Y. A purified anthraquinone-glycoside preparation from rhubarb ameliorates type 2 diabetes mellitus by modulating the gut microbiota and reducing inflammation. Front Microbiol. 2019;10:1423.","journal-title":"Front Microbiol"},{"key":"752_CR53","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","volume":"11","author":"NY Lee","year":"2020","unstructured":"Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11:882\u201399.","journal-title":"Gut Microbes"},{"key":"752_CR54","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.3390\/nu14245222","volume":"14","author":"Z Chen","year":"2022","unstructured":"Chen Z, Luo J, Jia M, Chai Y, Bao Y. Polygonatum sibiricum saponin exerts beneficial hypoglycemic effects in type 2 diabetes mice by improving hepatic insulin resistance and glycogen synthesis-related proteins. Nutrients. 2022;14:5222.","journal-title":"Nutrients"},{"key":"752_CR55","doi-asserted-by":"publisher","first-page":"112155","DOI":"10.1016\/j.biopha.2021.112155","volume":"143","author":"Y Chai","year":"2021","unstructured":"Chai Y, Luo J, Bao Y. Effects of Polygonatum sibiricum saponin on hyperglycemia, gut microbiota composition and metabolic profiles in type 2 diabetes mice. Biomed Pharmacother. 2021;143:112155.","journal-title":"Biomed Pharmacother"},{"key":"752_CR56","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/gutjnl-2019-318424","volume":"68","author":"ES Chambers","year":"2019","unstructured":"Chambers ES, Byrne CS, Morrison DJ, Murphy KG, Preston T, Tedford C, Garcia-Perez I, Fountana S, Serrano-Contreras JI, Holmes E, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut. 2019;68:1430\u20138.","journal-title":"Gut"},{"key":"752_CR57","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/fsn3.868","volume":"7","author":"Z Wang","year":"2019","unstructured":"Wang Z, Lam KL, Hu J, Ge S, Zhou A, Zheng B, Zeng S, Lin S. Chlorogenic acid alleviates obesity and modulates gut microbiota in high-fat-fed mice. Food Sci Nutr. 2019;7:579\u201388.","journal-title":"Food Sci Nutr"},{"key":"752_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","volume":"16","author":"F Shen","year":"2017","unstructured":"Shen F, Zheng R-D, Sun X-Q, Ding W-J, Wang X-Y, Fan J-G. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16:375\u201381.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"752_CR59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fmicb.2018.00061","volume":"9","author":"ET Saltzman","year":"2018","unstructured":"Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease. Front Microbiol. 2018;9:61.","journal-title":"Front Microbiol"},{"key":"752_CR60","doi-asserted-by":"publisher","first-page":"112948","DOI":"10.1016\/j.fct.2022.112948","volume":"164","author":"R Duan","year":"2022","unstructured":"Duan R, Huang K, Guan X, Li S, Xia J, Shen M, Sun Z, Yu Z. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice. Food Chem Toxicol. 2022;164:112948.","journal-title":"Food Chem Toxicol"},{"key":"752_CR61","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/nu13072135","volume":"13","author":"Q Guo","year":"2021","unstructured":"Guo Q, Tang Y, Li Y, Xu Z, Zhang D, Liu J, Wang X, Xia W, Xu S. Perinatal high-salt diet induces gut microbiota dysbiosis, bile acid homeostasis disbalance, and NAFLD in weanling mice offspring. Nutrients. 2021;13:2135.","journal-title":"Nutrients"},{"key":"752_CR62","doi-asserted-by":"publisher","first-page":"104942","DOI":"10.1016\/j.phrs.2020.104942","volume":"159","author":"B Hu","year":"2020","unstructured":"Hu B, Ye C, Leung EL, Zhu L, Hu H, Zhang Z, Zheng J, Liu H. Bletilla striata oligosaccharides improve metabolic syndrome through modulation of gut microbiota and intestinal metabolites in high fat diet-fed mice. Pharmacol Res. 2020;159:104942.","journal-title":"Pharmacol Res"},{"key":"752_CR63","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"A Agus","year":"2018","unstructured":"Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716\u201324.","journal-title":"Cell Host Microbe"},{"key":"752_CR64","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1096\/fj.201800544","volume":"32","author":"M Beaumont","year":"2018","unstructured":"Beaumont M, Neyrinck AM, Olivares M, Rodriguez J, de Rocca Serra A, Roumain M, Bindels LB, Cani PD, Evenepoel P, Muccioli GG, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J. 2018;32:6681.","journal-title":"FASEB J"},{"key":"752_CR65","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881\u201391.","journal-title":"Gut"},{"key":"752_CR66","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/jcb.27635","volume":"120","author":"J Chen","year":"2019","unstructured":"Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem. 2019;120:2713\u201320.","journal-title":"J Cell Biochem"},{"key":"752_CR67","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/hep.23831","volume":"52","author":"G Brufau","year":"2010","unstructured":"Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F, Murphy EJ. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010;52:1455\u201364.","journal-title":"Hepatology"},{"key":"752_CR68","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2174\/1389203717666160627074017","volume":"18","author":"S Hu","year":"2017","unstructured":"Hu S, Han M, Rezaei A, Li D, Wu G, Ma X. L-Arginine modulates glucose and lipid metabolism in obesity and diabetes. Curr Protein Pept Sci. 2017;18:599\u2013608.","journal-title":"Curr Protein Pept Sci"},{"key":"752_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MCO.0000000000000233","volume":"19","author":"JC Marini","year":"2016","unstructured":"Marini JC. Interrelationships between glutamine and citrulline metabolism. Curr Opin Clin Nutr Metab Care. 2016;19:62\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"752_CR70","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/01.CCM.0000162680.52397.97","volume":"33","author":"DA De-Souza","year":"2005","unstructured":"De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med. 2005;33:1125\u201335.","journal-title":"Crit Care Med"},{"key":"752_CR71","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3945\/jn.115.215517","volume":"145","author":"C Sellmann","year":"2015","unstructured":"Sellmann C, Jin CJ, Degen C, De Bandt JP, Bergheim I. Oral glutamine supplementation protects female mice from nonalcoholic steatohepatitis. J Nutr. 2015;145:2280\u20136.","journal-title":"J Nutr"},{"key":"752_CR72","doi-asserted-by":"publisher","first-page":"e0177464","DOI":"10.1371\/journal.pone.0177464","volume":"12","author":"W Hu","year":"2017","unstructured":"Hu W, Pan X, Abbas HMK, Li F, Dong W. Metabolites contributing to Rhizoctonia solani AG-1-IA maturation and sclerotial differentiation revealed by UPLC-QTOF-MS metabolomics. PLoS ONE. 2017;12:e0177464.","journal-title":"PLoS ONE"},{"key":"752_CR73","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3945\/jn.111.153825","volume":"142","author":"JC Marini","year":"2012","unstructured":"Marini JC. Arginine and ornithine are the main precursors for citrulline synthesis in mice. J Nutr. 2012;142:572\u201380.","journal-title":"J Nutr"},{"key":"752_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clnu.2015.01.021","volume":"35","author":"P Jegatheesan","year":"2016","unstructured":"Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N, Waligora-Dupriet AJ, Bergheim I, Cynober L, De-Bandt JP. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr. 2016;35:175\u201382.","journal-title":"Clin Nutr"},{"key":"752_CR75","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1210\/jc.2018-00546","volume":"103","author":"F Ottosson","year":"2018","unstructured":"Ottosson F, Smith E, Melander O, Fernandez C. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab. 2018;103:3060\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"752_CR76","doi-asserted-by":"publisher","first-page":"e4985","DOI":"10.1002\/bmc.4985","volume":"35","author":"B Zou","year":"2021","unstructured":"Zou B, Sun Y, Xu Z, Chen Y, Li L, Lin L, Zhang S, Liao Q, Xie Z. Rapid simultaneous determination of gut microbial phenylalanine, tyrosine, and tryptophan metabolites in rat serum, urine, and faeces using LC-MS\/MS and its application to a type 2 diabetes mellitus study. Biomed Chromatogr. 2021;35:e4985.","journal-title":"Biomed Chromatogr"},{"key":"752_CR77","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3390\/nu12061848","volume":"12","author":"J Kim","year":"2020","unstructured":"Kim J, Choi JH, Oh T, Ahn B, Unno T. Codium fragile ameliorates high-fat diet-induced metabolism by modulating the gut microbiota in mice. Nutrients. 2020;12:1848.","journal-title":"Nutrients"},{"key":"752_CR78","doi-asserted-by":"publisher","first-page":"117864691983455","DOI":"10.1177\/1178646919834550","volume":"12","author":"EL Paley","year":"2019","unstructured":"Paley EL. Diet-related metabolic perturbations of gut microbial shikimate pathway-tryptamine-tRNA aminoacylation-protein synthesis in human health and disease. Int J Tryptophan Res. 2019;12:1178646919834550.","journal-title":"Int J Tryptophan Res"},{"key":"752_CR79","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fimmu.2020.00557","volume":"11","author":"S Cussotto","year":"2020","unstructured":"Cussotto S, Delgado I, Anesi A, Dexpert S, Aubert A, Beau C, Forestier D, Ledaguenel P, Magne E, Mattivi F, Capuron L. Tryptophan metabolic pathways are altered in obesity and are associated with systemic inflammation. Front Immunol. 2020;11:557.","journal-title":"Front Immunol"},{"key":"752_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0007114514000440","volume":"112","author":"Y Ritze","year":"2014","unstructured":"Ritze Y, Bardos G, Hubert A, Bohle M, Bischoff SC. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice. Br J Nutr. 2014;112:1\u20137.","journal-title":"Br J Nutr"},{"key":"752_CR81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fcimb.2018.00013","volume":"8","author":"J Gao","year":"2018","unstructured":"Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13.","journal-title":"Front Cell Infect Microbiol"},{"key":"752_CR82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2011.06.020","volume":"94","author":"K Hara","year":"2011","unstructured":"Hara K, Hirowatari Y, Shimura Y, Takahashi H. Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease. Diabetes Res Clin Pract. 2011;94:167\u201371.","journal-title":"Diabetes Res Clin Pract"},{"key":"752_CR83","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.cmet.2020.03.006","volume":"31","author":"BJ Saeedi","year":"2020","unstructured":"Saeedi BJ, Liu KH, Owens JA, Hunter-Chang S, Camacho MC, Eboka RU, Chandrasekharan B, Baker NF, Darby TM, Robinson BS, et al. Gut-resident Lactobacilli activate hepatic Nrf2 and protect against oxidative liver injury. Cell Metab. 2020;31:956-968e955.","journal-title":"Cell Metab"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-023-00752-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:08:05Z","timestamp":1684386485000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-023-00752-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s13020-023-00752-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2480813\/v1","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal\nexperiments conducted in this study were approved\nby the Animal Care and Ethics Committee of Beijing University of Chinese\nMedicine (license number: BUCM-4-2021040108-2121) and conformed to internationally recognized\nprinciples of laboratory animal use and care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}